Medibio (ASX: MEB) (OTC: MDBIF) Mental health & wellness monitoring technologies

 

 

 

 

 

 

 

Medibio (ASX: MEB) (OTC: MDBIF) CEO Interview with David Kaysen. Mr. Kaysen recently came on board as the new CEO, in this interview he discusses Medibio's mental health monitoring technologies, ongoing progress towards full-scale commercializing, and his background in running small-cap med-tech companies.  Kaysen sees 2019 as a "very important year for Medibio" with commercialization rollout, capital raising and FDA regulatory approvals. 

This content is available to members only.

If you are an existing member, please LOGIN

Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires June 15, 2019.

Register New Account

Free Membership

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.